Stockreport

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

HUTCHMED (China) Limited - American Depositary Shares  (HCM) 
NASDAQ:AMEX Investor Relations: chi-med.com/investors/information-for-shareholders
PDF — Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib already approved in s [Read more]